Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | EML4 - NTRK3 |
Gene Variant Detail | |
Relevant Treatment Approaches | Larotrectinib |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
EML4 - NTRK3 | Advanced Solid Tumor | predicted - sensitive | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230). | 30279230 | |
EML4 - NTRK3 | Advanced Solid Tumor | predicted - sensitive | Entrectinib | Case Reports/Case Series | Actionable | In a Phase Ib/II trial (STARTRK-NG), a patient with an advanced solid tumor harboring EML4-NTRK3 demonstrated a partial response when treated with Rozlytrek (entrectinib) (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 107-107; NCT02650401). | detail... | |
EML4 - NTRK3 | high grade glioma | predicted - sensitive | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Xalkori (crizotinib) resulted in inhibition of cell growth in a glioma cell line harboring EML4-NTRK3 in culture (PMID: 25485619). | 25485619 | |
EML4 - NTRK3 | thyroid gland papillary carcinoma | predicted - sensitive | Entrectinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with papillary thyroid carcinoma harboring EML4-NTRK3 demonstrated a 69.7% decrease in disease burden after 34 cycles of treatment with Rozlytrek (entrectinib) (PMID: 32457407). | 32457407 | |
EML4 - NTRK3 | lung non-small cell carcinoma | predicted - sensitive | Entrectinib | Case Reports/Case Series | Actionable | In a Phase II trial (TRIDENT-1), a patient with metastatic non-small cell lung cancer harboring EML4-NTRK3 achieved a partial response during 12 months of treatment with Rozlytrek (entrectinib) (PMID: 34625502; NCT03093116). | 34625502 | |
EML4 - NTRK3 | congenital fibrosarcoma | predicted - sensitive | Entrectinib | Case Reports/Case Series | Actionable | In a Phase I/II trial, Rozlytrek (entrectinib) treatment resulted in a partial response lasting 13.8 months in a patient with infantile fibrosarcoma harboring EML4-NTRK3 (PMID: 35395680; NCT02650401). | 35395680 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|